- |||||||||| Erbitux (cetuximab) / Eli Lilly
Trial primary completion date, Metastases: Nordic 8 - A Phase II Trial (clinicaltrials.gov) - Jan 22, 2015 P2, N=180, Recruiting, Recruiting --> Active, not recruiting Trial primary completion date: Sep 2014 --> Dec 2016
- |||||||||| Avastin (bevacizumab) / Roche
Trial primary completion date, Combination therapy, Metastases: Sorafenib Tosylate, Bevacizumab, Irinotecan Hydrochloride, Leucovorin Calcium, and Fluorouracil in Treating Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - Jan 15, 2015 P1, N=18, Active, not recruiting, Trial primary completion date: Jul 2015 --> Jul 2016 Trial primary completion date: Dec 2014 --> Mar 2015
- |||||||||| 5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg.
Enrollment open, Metastases: Rectal Cancer, Adjuvant Chemotherapy, FOLFOX(5-fluorouracil/Leucovorin/Oxaliplatin), Total Mesorectal Excision (clinicaltrials.gov) - Jan 15, 2015 P3, N=580, Recruiting, Trial primary completion date: Dec 2014 --> Mar 2015 Not yet recruiting --> Recruiting
- |||||||||| enoxaparin sodium / Generic mfg.
Enrollment change: Chemotherapy With or Without Enoxaparin in Pancreatic Cancer (clinicaltrials.gov) - Jan 8, 2015 P2/3, N=312, Completed, N=25 --> 1 | Active, not recruiting --> Terminated | Trial primary completion date: Oct 2017 --> Dec 2014; Slow accrual. N=540 --> 312
- |||||||||| saridegib oral (IPI 926 oral) / Infinity Pharma
Enrollment open, Trial initiation date, Trial primary completion date, Metastases: FOLFIRINOX Plus IPI-926 for Advanced Pancreatic Adenocarcinoma (clinicaltrials.gov) - Jan 2, 2015 P1, N=21, Recruiting, Trial primary completion date: Jan 2015 --> Jan 2017 Active, not recruiting --> Recruiting | Initiation date: Aug 2011 --> Nov 2014 | Trial primary completion date: Apr 2013 --> Nov 2017
- |||||||||| Trial primary completion date, Surgery, Metastases: Chemotherapy Followed by Surgery, Chemotherapy, and Radiation Therapy in Treating Patients With Locally Advanced Head And Neck Cancer (clinicaltrials.gov) - Dec 30, 2014
P2, N=30, Active, not recruiting, Active, not recruiting --> Recruiting | Initiation date: Aug 2011 --> Nov 2014 | Trial primary completion date: Apr 2013 --> Nov 2017 Trial primary completion date: Dec 2014 --> Dec 2015
- |||||||||| GVAX Pancreas (allogeneic GM-CSF-secreting tumor cells) / Novartis
Enrollment closed, Tumor cell: Pancreatic Tumor Cell Vaccine (GVAX), Cyclophosphamide, SBRT, and FOLFIRINOX in Patients With Resected Adenocarcinoma of the Pancreas (clinicaltrials.gov) - Dec 24, 2014 P=N/A, N=18, Active, not recruiting, Suspended --> Recruiting Recruiting --> Active, not recruiting
- |||||||||| leucovorin calcium / Generic mfg., cisplatin / Generic mfg., gemcitabine / Generic mfg.
Trial primary completion date, Metastases: Fluorouracil, Leucovorin, Gemcitabine, and Cisplatin in Treating Patients With Metastatic or Unresectable Adenocarcinoma of the Urothelium or Urachal Remnant (clinicaltrials.gov) - Dec 19, 2014 P2, N=46, Active, not recruiting, Recruiting --> Active, not recruiting Trial primary completion date: Feb 2015 --> Feb 2017
|